Table 3.
Dataset | Metric of Interest | Gradient Boosting Model | Benchmark Logistic Regression Model | Benchmark Neural Network Model |
---|---|---|---|---|
Training set∗ (via 10-fold cross validation) | AUC, mean (95% CI) | 0.729 (0.690‒0.767) | 0.653 (0.599‒0.706) | 0.696 (0.657‒0.734) |
Sensitivity, mean (95% CI) | 0.670 (0.477‒0.862) | 0.610 (0.483‒0.738) | 0.664 (0.484‒0.843) | |
Specificity, mean (95% CI) | 0.611 (0.412‒0.809) | 0.592 (0.450‒0.733) | 0.585 (0.410‒0.760) | |
Prospective validation set† | AUC | 0.721 | 0.689 | 0.707 |
Sensitivity | 0.622 | 0.914 | 0.904 | |
Specificity | 0.713 | 0.233 | 0.308 | |
State LTCF outcome rates‡ | Correlation between median risk index and state LTCF case rates by state, Pearson correlation coefficient | 0.859 | 0.384 | 0.731 |
Correlation between median risk index and LTCF deaths rates by state, Pearson correlation coefficient | 0.856 | 0.335 | 0.705 |
NHs from Massachusetts, Georgia, and New Jersey with outcomes reported on April 20, 2020.
NHs from California with outcomes reported on May 11, 2020.
LTCF-related COVID-19 case and death rates reported on May 11th by states across the United States.